11 found
Order:
Disambiguations
Joel Lexchin [8]J. Lexchin [2]Joel R. Lexchin [1]
  1.  5
    Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs.Donald W. Light, Joel Lexchin & Jonathan J. Darrow - 2013 - Journal of Law, Medicine and Ethics 41 (3):590-600.
    No categories
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   13 citations  
  2.  36
    Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs.Donald W. Light, Joel Lexchin & Jonathan J. Darrow - 2013 - Journal of Law, Medicine and Ethics 41 (3):590-600.
    Over the past 35 years, patients have suffered from a largely hidden epidemic of side effects from drugs that usually have few offsetting benefits. The pharmaceutical industry has corrupted the practice of medicine through its influence over what drugs are developed, how they are tested, and how medical knowledge is created. Since 1906, heavy commercial influence has compromised congressional legislation to protect the public from unsafe drugs. The authorization of user fees in 1992 has turned drug companies into the FDA's (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   12 citations  
  3.  83
    Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications. [REVIEW]Joel Lexchin - 2012 - Science and Engineering Ethics 18 (2):247-261.
    Pharmaceutical companies fund the bulk of clinical research that is carried out on medications. Poor outcomes from these studies can have negative effects on sales of medicines. Previous research has shown that company funded research is much more likely to yield positive outcomes than research with any other sponsorship. The aim of this article is to investigate the possible ways in which bias can be introduced into research outcomes by drawing on concrete examples from the published literature. Poorer methodology in (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   13 citations  
  4.  11
    Legislative Regulation and Ethical Governance of Medical Research in Different European Union Countries.P. Veerus, J. Lexchin & E. Hemminki - 2014 - Journal of Medical Ethics 40 (6):409-413.
    Objective To obtain information about the similarities and differences in regulating different types of medical research in the European Union .Methods Web searches were performed from September 2009 to January 2011. Notes on pre-determined topics were systematically taken down from the web pages. The analysis relied only on documents and reports available on the web, reflecting the situation at the end of 2010.Results In several countries, regulatory legislation applied only to clinical trials on drugs and medical devices, in other states (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  5.  28
    Will Lower Drug Prices Jeopardize Drug Research? A Policy Fact Sheet.Donald W. Light & Joel Lexchin - 2004 - American Journal of Bioethics 4 (1):1 – 4.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  6.  17
    Fromcaveat Emptortocaveat Venditor: Time to Stop the Influence of Money on Practice Guideline Development.Lisa Cosgrove, Allen F. Shaughnessy, Emily E. Wheeler, Sheldon Krimsky, Shannon M. Peters, Darren J. Freeman-Coppadge & Joel R. Lexchin - 2014 - Journal of Evaluation in Clinical Practice 20 (6):809-812.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  7.  8
    Medicines Information and the Regulation of the Promotion of Pharmaceuticals.Teresa Leonardo Alves, Joel Lexchin & Barbara Mintzes - 2019 - Science and Engineering Ethics 25 (4):1167-1192.
    Many factors contribute to the inappropriate use of medicines, including not only a lack of information but also inaccurate and misleading promotional information. This review examines how the promotion of pharmaceuticals directly affects the prescribing and use of medicines. We define promotion broadly as all actions taken directly by pharmaceutical companies with the aim of enhancing product sales. We look in greater detail at promotion techniques aimed at prescribers, such as sales representatives, pharmaceutical advertisements in medical journals and use of (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  8.  16
    Of Money and Trust in Medical Care Redux.Joel Lexchin - 2012 - Mens Sana Monographs 10 (1):143.
    Should we be concerned about financial conflicts of interest (COI) between doctors and the pharmaceutical industry? Some people will say no as there are clearly doctors who celebrate the relationship. Others say that it does not matter to patients, but the evidence says otherwise. Financial COI is different from other types of conflicts because it is voluntary and can be refused. Finally, it is not just the large gifts that are a problem, the small ones also create a "gift relationship." (...)
    Direct download (12 more)  
     
    Export citation  
     
    Bookmark  
  9.  5
    Regulating Information or Allowing Deception? Pharmaceutical Sales Visits in Canada, France, and the United States.Roojin Habibi, Line Guénette, Joel Lexchin, Ellen Reynolds, Mary Wiktorowicz & Barbara Mintzes - 2016 - Journal of Law, Medicine and Ethics 44 (4):602-613.
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  10.  2
    Voluntary Self-Regulatory Codes: What Should We Expect?Joel Lexchin - 2003 - American Journal of Bioethics 3 (3):49-50.
  11. Of Money And Trust In Biomedical Care.J. Lexchin - 2007 - Mens Sana Monographs 5 (1):7.
    Direct download (9 more)  
     
    Export citation  
     
    Bookmark